Tepotinib is an oral c-Met inhibitor developed by Merck KGaA Pharmaceuticals.Tepotinib is the first small molecule inhibitor for the treatment of Met mutant non-small cell lung cancer.This article summarizes the synthesis process of Tepotinib to provide new ideas for the design of the synthesis routes of Tepotinib.
万方数据
维普
